Crossmark

A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia

Crossref DOI link: https://doi.org/10.1186/s12906-020-03071-7

Published Online: 2020-09-15

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pingali, Usharani http://orcid.org/0000-0002-9300-8022
Nutalapati, Chandrasekhar

Koilagundla, Niranjan

Taduri, Gangadhar
License Information

Text and Data Mining valid from 2020-09-15

Version of Record valid from 2020-09-15
More Information

Article History

Received: 25 November 2019

Accepted: 2 September 2020

First Online: 15 September 2020

Ethics approval and consent to participate

: The present study was approved by Nizam’s Institute of Medical Sciences -Institutional Ethics Committee. Review letter No.EC/NIMS/1793/2016, 19th ESGS No.389/2016. Written informed consent was taken from all the subjects before participation in the study.

: Not Applicable.

: Authors declare that we have no competing interests.

Document is current

Any future updates will be listed below